ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
ARS Pharmaceuticals, Inc. (SPRY) Misses Q1 EPS by 12c, Beats on Revenue
May 15, 2026 6:01 AM EDTARS Pharmaceuticals, Inc. (NASDAQ: SPRY) reported Q1 EPS of ($0.61), $0.12 worse than the analyst estimate of ($0.49). Revenue for the quarter came in at $22.7 million versus the consensus estimate of $22.67 million.
For earnings history and earnings-related data on ARS Pharmaceuticals, Inc. (SPRY) click here.
... More